Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relypsa Inc.

Division of Vifor Pharma Group
www.relypsa.com

Latest From Zambon Co. SPA

Newron CEO On Xadago & Upcoming Pipeline Milestones

Newron CEO Stefan Weber joins Scrip to discuss the company's recently approved Parkinson's therapy Xadago (safinamide), as well as development timelines for Newron's other pipeline candidates.

Neurology Approvals

Newron's Parkinson's Disease Drug Xadago Priced At $600-700/Month

First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.

Approvals Regulation

Newron's Parkinson's Drug Xadago Has Narrower Indication Than Teva's Azilect

After overcoming regulatory hurdles, Newron may have tough time competing in US against market stalwart Azilect; eight Parkinson's drugs are in Phase III trials.

Approvals Regulation

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vifor Pharma Group
  • Senior Management
  • John A Orwin, CEO
    Kristine M Ball, SVP, CFO
    Stephen D Harrison, PhD, SVP, CSO
    Lance Berman, MD, SVP, CMO
    Scott Garland, SVP, Chief Commercial Officer
    Camille Landis, VP, Bus. Dev.
  • Contact Info
  • Relypsa Inc.
    Phone: (650) 421-9500
    100 Cardinal Way
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register